Review
Pharmacology & Pharmacy
Lin Cheng
Summary: Adverse drug reactions, particularly SJS and TEN, are a significant public health concern with high mortality rates and ineffective treatment options. Factors such as infections, mutations in drug metabolic enzymes, and immune responses contribute to SJS/TEN development. Future research directions include epigenetics, metabolites, and regulatory T cells.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Hua-Ching Chang, Tsung-Jen Wang, Ming-Hsiu Lin, Ting-Jui Chen
Summary: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases caused by drugs. The effectiveness of systemic immunomodulating treatments for SJS/TEN is still controversial, but cyclosporine and biologic anti-TNF-alpha have shown promising results. Combination treatments are also being explored. Large-scale randomized controlled trials are needed for more definitive evidence. Advances in understanding the pathogenesis of SJS/TEN may inspire the discovery of potential therapeutic targets.
Review
Medicine, General & Internal
Tais Hitomi Wakamatsu, Myrna Serapiao dos Santos, Telma Pereira Barreiro, Ana Estela Besteti Pires Ponce Sant'Anna, Fabiola Murta, Alexandre Xavier da Costa, Leonardo Guedes C. Marculino, Rafael Jorge Alves de Alcantara, Charles Costa de Farias, Jose Alvaro Pereira Gomes
Summary: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute and potentially fatal inflammatory reactions triggered by specific medications and infections, with genetic variations increasing the risk. In Brazil, certain medications like cold medicine have been found to be most commonly associated with SJS/TEN, leading to severe ocular complications in patients of mixed African and European ancestry. Changes in conjunctival flora and new treatment options for ocular management in SJS/TEN patients have been highlighted, including the use of innovative techniques like amniotic membrane transplantation and minor salivary gland transplantation.
FRONTIERS IN MEDICINE
(2021)
Article
Ophthalmology
Leangelo N. Hall, Swapna S. Shanbhag, Ramy Rashad, James Chodosh, Hajirah N. Saeed
Summary: The study evaluated the effect of systemic cyclosporine on ocular disease in SJS/TEN patients and found no significant association between the use of systemic cyclosporine and chronic ocular complications in this small cohort.
Article
Medicine, General & Internal
David Hui-Kang Ma, Tsung-Ying Tsai, Li-Yen Pan, Shin-Yi Chen, Ching-Hsi Hsiao, Lung-Kun Yeh, Hsin-Yuan Tan, Chun-Wei Lu, Chun-Bing Chen, Wen-Hung Chung
Summary: Recent advancements in the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have shown progress in improving ophthalmic outcomes. A study of 119 patients at Chang Gung Memorial Hospital Linkou Branch from 2010 to 2020 revealed a high incidence of severe ocular complications (SOCs) in the acute stage, with antiepileptic drugs being a common cause. Furthermore, early treatment with etanercept and amniotic membrane transplantation (AMT) showed promising outcomes in reducing chronic ocular sequelae in SJS/TEN patients.
FRONTIERS IN MEDICINE
(2021)
Review
Medicine, General & Internal
Mayumi Ueta
Summary: SJS/TEN with SOC is an acute inflammatory reaction that affects mucosa and skin, with cold medicines identified as the main causative drugs. Specific genes such as TLR3, PTGER3, and IKZF1 have been found to be significantly associated with SJS/TEN with SOC. In chronic stage, tear cytokines such as IL-8, IL-6, and IFN-gamma were upregulated, while IP-10 was downregulated, contributing to the chronic ocular surface inflammation in these patients.
FRONTIERS IN MEDICINE
(2021)
Article
Medicine, General & Internal
Ekaterina A. Nikitina, Daria S. Fomina, Ulyana A. Markina, Sergey S. Andreev, Yuri V. Streltsov, Tatiana S. Kruglova, Marina S. Lebedkina, Alexander V. Karaulov, Maryana A. Lysenko
Summary: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare syndromes characterized by necrotic skin and mucosal lesions. Drug-induced mechanisms are the most common cause, with certain drugs posing a higher risk. There is no gold standard treatment, but TNF-α inhibitors have shown promise in SJS/TEN cases.
FRONTIERS IN MEDICINE
(2023)
Article
Dermatology
Ting-Jung Hsu, Hsu-Hang Yeh, Chih-Hung Lee, Kwei-Lan Liu
Summary: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are potentially fatal adverse drug reactions. The most common culprit drug is carbamazepine, which has a strong association with HLA-B*15:02. There is no statistically significant correlation between in-hospital stay and the average daily dose of corticosteroids.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2021)
Review
Medicine, General & Internal
Chie Sotozono, Mayumi Ueta, Shigeru Kinoshita
Summary: J-SCAR issued the official Diagnostic Criteria for SJS/TEN in 2005, which includes specific ocular findings; ocular involvement was observed in 77% of cases and the incidence of ocular sequelae may increase with the severity of acute ocular symptoms; controlling inflammation and stem cell loss is crucial for successful treatment of eyes affected by SJS/TEN from onset to chronic stage.
FRONTIERS IN MEDICINE
(2021)
Review
Medicine, General & Internal
Derek Metcalfe, Omer Iqbal, James Chodosh, Charles S. Bouchard, Hajirah N. Saeed
Summary: Stevens-Johnson syndrome and toxic epidermal necrolysis are severe immune-mediated mucocutaneous diseases that often involve the eyes and can result in corneal blindness. Early treatment is crucial in reducing the severity of chronic disease, with interventions such as amniotic membrane transplantation showing promise. However, aggressive acute treatment does not guarantee prevention of severe chronic ocular disease.
FRONTIERS IN MEDICINE
(2021)
Article
Ophthalmology
Ramy Rashad, Swapna S. Shanbhag, James Kwan, James Chodosh, Saleh Saeed, Hajirah N. Saeed
Summary: This study compared the severity of chronic ocular complications in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis induced by lamotrigine vs. trimethoprim-sulfamethoxazole. It found that patients with lamotrigine-induced SJS/TEN had worse visual acuity at the most recent visit and a higher prevalence of severe ocular complications compared to those with trimethoprim-sulfamethoxazole-induced SJS/TEN.
Article
Oncology
Yanhong Shou, Lu Yang, Yongsheng Yang, Xiaohua Zhu, Feng Li, Bo Yin, Yingyan Zheng, Jinhua Xu
Summary: This study validated the predictive ability of risk models in patients with SJS/TEN in China, with SCORTEN showing good discrimination performance, calibration, and accuracy. Refined AS or ABCD-10 model may be an option when SCORTEN variables are not available.
FRONTIERS OF MEDICINE
(2021)
Article
Dermatology
Pan Lv, Jiangxia Huang, Qianru Yang, Ting Yang, Xianwei Cao, Ougen Liu, Zhibin Zhang
Summary: This study analyzed the expression profiles of circRNAs in peripheral blood mononuclear cells of SJS/TEN patients and found a correlation between circRNA expression and disease severity. Specifically, hsa_circ_0083619 was identified as a potential indicator for SJS/TEN severity and a circRNA-miRNA-mRNA network was constructed. The study suggests that the hsa_circ_0083619/miR-18a-5p/BCL2L10 axis may play a role in the pathogenesis of SJS/TEN.
EXPERIMENTAL DERMATOLOGY
(2023)
Review
Medicine, General & Internal
Eri Tsukagoshi, Yoichi Tanaka, Yoshiro Saito
Summary: Drug-related Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adverse drug reactions, with predicting their onset remaining challenging. Pharmacogenomic information on drug labels may differ among countries, but CPIC guidelines provide a scientifically sound goal for future pharmacogenomic implementation.
FRONTIERS IN MEDICINE
(2021)
Article
Dermatology
Yasmin Chia Chia Liew, Karen Jui Lin Choo, Choon Chiat Oh, Shiu Ming Pang, Yi Wei Yeo, Haur Yueh Lee
Summary: This study evaluated the differences between Mycoplasma-related and drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. The results showed no significant differences in baseline characteristics and extent of involvement, but significant differences in mortality rates between the two groups.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Letter
Critical Care Medicine
Ya-Yu Lee, Chia-Chin Wu, Yih-Jyh Lee, Cho-Han Chiang, Kevin Sheng-Kai Ma, James Cheng-Chung Wei
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Letter
Rheumatology
Shu-Hao Hsu, Wei-Wei Liu, Yung-Heng Lee, Kevin Sheng-Kai Ma
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Editorial Material
Dentistry, Oral Surgery & Medicine
Chuan-Yi Kao, Chia-Tze Kao, Kevin Sheng-Kai Ma, Tsui-Hsien Huang
JOURNAL OF DENTAL SCIENCES
(2023)
Article
Cardiac & Cardiovascular Systems
Cho-Han Chiang, Cho-Hung Chiang, Cho-Hsien Chiang, Kevin Sheng-Kai Ma, Chun-Yu Peng, Yuan Ping Hsia, Chuan-Sheng Horng, Cheng-Ying Chen, Yu-Cheng Chang, Xin Ya See, Yuan-Jen Chen, Shih-Syuan Wang, Giselle A. Suero-Abreu, L. R. Peterson, Paaladinesh Thavendiranathan, Philippe Armand, Cheng-Ming Peng, Her-Shyong Shiah, Tomas G. Neilan
Summary: This study demonstrates that SGLT2 inhibitors can reduce the incidence of heart failure and prolong overall survival in patients with diabetes mellitus and cancer.
Letter
Dermatology
Shuo-Yan Gau, Chien-Ying Lee, Yu-Hsiang Kuan, Kevin Sheng-Kai Ma, James Cheng-Chung Wei
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Letter
Oncology
En-Wei Chang, Chia-Wen Liu, Chen Dong, Yung-Shuo Kao, Kevin Sheng-Kai Ma, James Cheng-Chung
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Letter
Rheumatology
Chia-Ling Tsao, Yung-Heng Lee, Chen Dong, Cheng-Siu Chang, Kevin Sheng-Kai Ma
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Editorial Material
Rheumatology
Pei-En Kao, Yung-Heng Lee, Kevin Sheng-Kai Ma, Amy Ker, Ying-Ying Leung
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Editorial Material
Rheumatology
Kevin Sheng-Kai Ma, Yung-Heng Lee, Chia-Jen Lin, Po-Cheng Shih, James Cheng-Chung Wei
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Letter
Oncology
Yu-Wen Huang, Wei-Ting Huang, Chen Dong, Kevin Sheng-Kai Ma, Yung-Shuo Kao
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Editorial Material
Rheumatology
Yu-Han Chen, Wen Han Tsai, Ying-Cheng Chen, Kun-Hui Chen, Kevin Sheng-Kai Ma
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Yu-Han Chen, Yuan-Ti Lee, Kevin Sheng-Kai Ma
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Editorial Material
Rheumatology
Kevin Sheng-Kai Ma, Pei-En Kao, Su Boon Yong, Kun-Hui Chen
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Shu-Yen Chan, Li-Yu Lu, Sheng-Yi Lin, Kevin Sheng-Kai Ma
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Dentistry, Oral Surgery & Medicine
Li-Tzu Wang, Ping-Hao Chiang, Chi-Hsiang Chung, Mingyang Song, Sait Ashina, Wu-Chien Chien, Kevin Sheng-Kai Ma
Summary: This pilot study found a higher risk of head and neck cancers in patients with migraine, especially those with migraine with aura. Non-nasopharyngeal cancers were more commonly associated with migraine. Larger studies are needed to confirm these findings.
